PRP for Hip Arthritis: What Five Trials Actually Found

Most of the discussion around platelet-rich plasma, including on this site, has been about the knee. That is where the bulk of the research sits and where most patients start asking questions. The hip is a different joint with a different evidence base, and that evidence base is smaller. This post reports what the available trials found. It is a summary rather than a recommendation.

PRP is prepared from a patient's own blood and injected into the joint. If you want the mechanism explained from the beginning, our general guide to PRP for joint pain covers how it is drawn, spun, and delivered. For hip osteoarthritis the practical question is narrower: whether it does more than the alternatives, and how long any benefit lasts.

What the trials found

The review in question is "Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra-articular Injections in Hip Osteoarthritis: A Systematic Review of Randomized Clinical Trials", published in Cureus in October 2024 by Almutairi and Alazzeh. It included five randomized clinical trials with a combined 413 patients, with individual study sizes ranging from 43 to 111 participants.

Four of the five studies showed significant pain reduction with PRP, at timepoints ranging from 4 weeks to 12 months. Most trials also showed significant functional improvement, measured with the WOMAC index and the Harris Hip Score. The timepoints at which function improved were not consistent between trials, which is part of why the picture is harder to summarise than the knee literature.

Two findings ran against that pattern, and they matter as much as the positive ones. Di Sante and colleagues, in 2016, found significant pain reduction at 4 weeks that was not sustained at 16 weeks, and no significant functional improvement at either point. In one further study the benefits had diminished by the 12 month follow-up.

The comparison that matters clinically

For most patients the question is not whether PRP works in isolation, but how it compares to what would otherwise be offered. The usual injectable alternative is hyaluronic acid. Cortisone is the other common option, and I have written separately about how PRP and cortisone differ.

Two of the trials reported PRP outperforming hyaluronic acid, and it is worth being precise about which measure each one refers to. Dallari and colleagues found PRP better for pain reduction. Nouri and colleagues, in 2022, found it better for function, reporting "more significant functional improvement in PRP and PRP-HA groups compared to the HA group."

The remaining trials do not settle the comparison. For the other two, the review reports significant improvement in both groups but no result comparing PRP against hyaluronic acid, and for Di Sante it reports no such comparison at all. So the accurate summary is that where the review reports a direct comparison, PRP came out ahead, and that this covers a minority of the trials rather than all of them.

There is also a useful negative finding. Combining PRP with hyaluronic acid offered no additional benefit over PRP alone. That is worth knowing, because combination therapy is often presented as getting the best of both. In this review it did not outperform PRP by itself, while adding cost and another variable.

Safety, as reported

No major adverse events were reported across the five trials. That should be read for exactly what it is: a finding from five studies totalling 413 patients. A sample that size cannot characterise rare events.

Minor transient side effects were reported in some patients, including localized pain, warmth and stiffness. There was slightly more post-injection pain in the PRP groups than with hyaluronic acid alone. The safety data here are reassuring over the short term and simply do not speak to the long term.

Why the studies disagree

If you read about PRP for hip arthritis you will find results that look positive and results that look neutral. The explanation is not that some researchers are careless. It is that the studies were not doing the same thing.

The authors identify variability in PRP preparation methods as a limitation that complicates direct comparison between trials. PRP is not a single standardized product, and two preparations can both carry that name while differing in what they contain. This is the same issue the knee literature has been wrestling with, and it is a fair thing to ask any provider about directly.

Follow-up durations also varied, from 16 weeks to 12 months. A study ending at 16 weeks cannot tell you what happens at a year, and a study reporting benefit at six months is not contradicted by one that never looked past that point. Patient populations were diverse across the trials, which the authors note reduces generalizability. Methodological quality ranged from low to high risk of bias, by the authors' own assessment.

The practical consequence for a patient is that a generic question about "PRP" tends to produce a generic answer. Asking what preparation is used, and what the evidence looks like for your particular joint and stage of arthritis, is a more useful conversation.

Honest positioning

The review's own conclusion is that PRP "may offer significant advantages, especially for patients who do not respond to conventional treatments." That is a measured claim and it matches how I think about this.

Conservative care comes first. Activity modification, weight management where relevant, physical therapy, and appropriate use of oral medication address the load on the joint in a way an injection does not. Osteopathic manipulative treatment belongs in that same first tier, because hip pain is frequently driven by mechanics above and below the joint rather than by the joint alone. For many patients with hip osteoarthritis that combination keeps symptoms manageable for a long time. Injections are not first line and are not a substitute for the work that changes joint loading.

It is also worth being sure the hip joint is the source of the pain. Lateral hip pain in particular is often greater trochanteric pain syndrome rather than arthritis, and that is a different problem with a different treatment path.

For someone who has done those things and still has meaningful pain and functional limitation, PRP becomes a reasonable thing to discuss. Arthritis severity, age and individual goals all bear on whether it makes sense, and that assessment requires an examination and a review of imaging.

The evidence reviewed here is encouraging without being definitive. Five trials and 413 patients is a modest base, the preparation variability is real, and the long term data are thin. The honest answer to whether PRP works for hip arthritis is that it appears to reduce pain and improve function for some patients, that it beat hyaluronic acid in the two trials where the review reports a direct comparison, and that we do not yet know who benefits most or for how long.

That last gap is the one to ask your physician about, because it is the one that decides whether the treatment is right for you rather than for the average patient in a study.